Citizens JMP raised the firm’s price target on Protagonist Therapeutics (PTGX) to $69 from $67 and keeps an Outperform rating on the shares following the Q2 report. The company remains on track to submit its application for rusfertide in polycythemia vera next quarter, with two new candidates nearing clinical testing, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability
- Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress
- Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating
- Protagonist Therapeutics files automatic mixed securities shelf
- Protagonist Therapeutics reports Q2 EPS (55c), consensus (52c)